US Material Events SEC 8-K Filings — August 04, 2026

04-08-2026

Future FinTech Group Inc. (FTFT) entered into Securities Purchase Agreements on July 29, 2026, to issue and sell 30,000,000 shares of common stock at $1.00 per share for aggregate gross proceeds of $30,000,000. The offering was completed on July 30, 2026, and immediately following issuance the company had 32,080,831 shares outstanding. Wealth Index Capital Limited, controlled by former CEO and controlling shareholder Shanchun Huang, purchased 10,000,000 shares, increasing its beneficial ownership from approximately 27.0% to approximately 32.9%.

• · The offering was exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and/or Regulation S.
• · No underwriting discounts or commissions were paid, and no underwriter or placement agent was engaged.
• · The per-share purchase price was fixed at $1.00, which was at a premium to the Minimum Price as defined in Nasdaq Listing Rule 5635(d)(1)(A).
• · The company and purchasers agreed not to enter into a registration rights agreement; purchasers waived all registration rights, so the shares remain restricted securities.
• · An ownership limitation prevents any purchaser from beneficially owning more than 19.99% of outstanding common stock after issuance, unless stockholder approval is obtained.

04-08-2026

Angi Inc. reported Q2 2026 revenue of $248.0M, down 11% YoY from $278.2M, and a net loss of $230.7M vs. net income of $10.9M in Q2 2025, driven by a $235.2M non-cash goodwill and intangible impairment. Adjusted EBITDA fell 14% to $28.2M. Positively, Large Pro and National Partnership Revenue grew 20% for the second consecutive quarter, and International Revenue was approximately flat YoY. The company also launched a beta test of its AI Front Desk agent in July 2026.

• · Revenue per Lead increased 1% YoY in Q2 2026, reflecting a favorable shift in Pro mix toward the subscription product.
• · The company recorded an income tax benefit of $0.9 million in Q2 2026, with the effective rate below 21% due to the permanently non-deductible goodwill impairment.
• · Year-to-date Adjusted EBITDA was $51.2 million.
• · Since the debt repurchase program's inception (March 20, 2026) through May 5, 2026, the company repurchased $100.0 million aggregate principal amount of 2028 Senior Notes for $91.9 million cash, realizing an $8.4 million gain. No additional repurchases occurred after May 5, 2026.
• · U.S. segment operating loss was $239.0 million in Q2 2026, compared to operating income of $12.7 million in Q2 2025.
• · International segment operating income was $5.3 million in Q2 2026, up from $5.0 million in Q2 2025.
• · Consumer marketing expense increased to 41% of revenue in Q2 2026 from 35% in Q2 2025.
• · Fixed expense decreased to 17% of revenue in Q2 2026 from 22% in Q2 2025.
• · The company had 40.6 million absolute shares outstanding as of July 31, 2026, with potential dilution of 1.0 million shares from RSUs and MSUs (2.3% dilution).

04-08-2026

DataMEDS AI, Inc. (formerly Wellgistics Health, Inc.) entered into an Amended and Restated Letter of Intent on July 29, 2026, to acquire or exclusively license certain QOLPOM-related IP assets from EOS and Scilex, expand its PharmacyChain license with Datavault, and acquire a controlling interest in Tollo Health. Post-closing, the acquiring parties (EOS, Scilex, Datavault, HBA) are expected to own approximately 84.6% of the company's common stock, while existing public stockholders would hold only about 10.4%, representing massive dilution. The transaction remains subject to due diligence, definitive agreements, board and stockholder approvals, and Nasdaq requirements, with no guarantee of completion.

• · The LOI supersedes the Fully Binding Term Sheet dated May 18, 2026.
• · No preferred stock, convertible securities, or contingent conversion features are being issued as consideration.
• · Post-closing transfer restrictions include a 6-month lock-up for certain Acquisition Stock holders.
• · The Company must file a resale registration statement within 45 days of closing and use commercially reasonable efforts to have it declared effective within 90 days.
• · Exclusivity period runs through September 30, 2026, subject to a 30-day due diligence termination right for the Company.
• · The Company will appoint two new management team members and four board designees (one from each of EOS, Scilex, Datavault, HBA) post-closing.
• · The transaction is subject to Nasdaq requirements, including potential approval of an initial listing application if treated as a change of control.

04-08-2026

PAMT CORP reported Q2 2026 net loss of $7.4 million, improved from a $9.6 million loss in Q2 2025, with revenue up 8.9% to $164.7 million. Operating loss narrowed to $10.4 million from $11.1 million, and truck productivity (miles per truck per day) increased 12.8% YoY while empty miles improved to 7.4% from 8.9%. However, the operating ratio worsened to 114.2% from 112.5%, revenue per total mile (before fuel surcharge) declined to $1.98 from $2.04, and total loads fell 8.1% YoY. The company also appointed Daniel C. Kleine as CFO effective July 30, 2026.

• · Q2 2026 revenue before fuel surcharge was $136.9M vs $133.8M in Q2 2025.
• · Fuel surcharge revenue increased to $27.8M from $17.3M YoY.
• · Salaries, wages and benefits rose slightly to $41.4M from $40.9M.
• · Insurance and claims expense jumped to $8.7M from $5.2M, partly due to the $3.1M one-time accrual.
• · Gain on disposition of assets fell sharply to $0.6M from $4.4M.
• · Interest expense increased to $4.6M from $4.0M.
• · Non-operating income more than doubled to $5.1M from $2.3M.
• · Cash and cash equivalents dropped to $18.2M from $35.2M at Dec 31, 2025.
• · Trade accounts receivable increased to $88.9M from $66.9M.
• · Marketable equity securities decreased to $38.7M from $48.5M.
• · Total assets declined to $670.3M from $697.9M.
• · Logistics segment revenue grew to $50.8M from $41.0M, with operating ratio improving to 96.4% from 98.7%.
• · For the six months ended June 30, 2026, net loss was $7.5M vs $17.8M in the prior year period.
• · Six-month operating loss improved to $10.7M from $20.3M.
• · Six-month revenue before fuel surcharge declined to $259.6M from $270.5M.

04-08-2026

HPS Corporate Capital Solutions Fund entered into Amendment No. 2 to its Senior Secured Revolving Credit Agreement, dated August 4, 2026, with JPMorgan Chase Bank as administrative and collateral agent and the lenders party thereto. The amendment modifies terms of the existing credit facility originally dated April 8, 2024, and was preceded by a prior amendment on April 23, 2025. The filing does not disclose any new borrowing amounts, changes to the facility size, or financial performance metrics, making this a routine administrative amendment with no material financial impact disclosed.

• · The amendment became effective on August 4, 2026 (Second Amendment Effective Date).
• · Conditions precedent included receipt of executed counterparts, legal opinions from Dechert LLP (New York and Luxembourg counsel) and Milbank LLP (special New York counsel to JPMCB), corporate documents, an officer's certificate, a borrowing base certificate, and unaudited financial statements for the quarter ended June 30, 2026.
• · The borrower represented that representations and warranties in Article III of the Credit Agreement remain true and correct as of the effective date.
• · No changes to the credit facility size, interest rate, maturity, or financial covenants were disclosed in the filing.

04-08-2026

Integer Holdings Corporation filed an 8-K on August 4, 2026, disclosing the adoption of amended and restated By-laws, effective August 2, 2026. The amendments primarily update procedural rules for stockholder meetings, including advance notice requirements for proposals and director nominations, and clarify the powers of the presiding officer. This is a routine governance update with no immediate financial impact.

• · The amended By-laws were adopted by the Board of Directors on August 2, 2026.
• · Stockholder proposals must be submitted between 90 and 120 days prior to the anniversary of the prior year's annual meeting.
• · If the annual meeting date is advanced by more than 20 days or delayed by more than 60 days, the notice deadline is the later of 90 days before the meeting or 7 days after public disclosure of the new date.
• · The presiding officer at stockholder meetings has broad authority to determine order of business and impose time limits on stockholder remarks.
• · Special meetings may be called by the Board, Chairman, or CEO; business at special meetings is limited to items specified in the notice.

04-08-2026

Wheels Up reported second-quarter 2026 revenue of $182.0 million, down 4% year over year, while gross profit increased to $9.6 million and Adjusted EBITDAR loss improved 27% to $19.9 million. However, net loss widened 30% to $107 million, Total Gross Bookings declined 8% to $241.8 million, and Adjusted Contribution fell 2% to $22.5 million; the company also completed a $100 million term loan and a $68 million aircraft financing facility, while extending Delta’s $100 million revolving credit facility commitment through September 20, 2028.

• · Private Jet Gross Bookings were $190,690 thousand in the second quarter of 2026 versus $208,326 thousand in the prior-year period, a decrease of 8%.
• · Adjusted Contribution Margin was 12.4% versus 12.2%, an improvement of 0.2 percentage points, although the company estimated approximately 6 points of year-over-year margin pressure from the prior-year sale of non-core services businesses and business transformation inefficiencies.
• · On-Time Performance (D-60) was 94.4% versus 88.8%, while the 3+ Hour Delay Rate fell to 1.2% from 2.8%.
• · Six-month gross profit increased 596% to $7,577 thousand from $1,088 thousand.
• · Six-month Adjusted EBITDA loss improved 8% to $56,716 thousand from $61,881 thousand.
• · The company reported a combined $13 million increase in interest expense and aircraft lease costs and a $13 million non-cash impairment charge associated with legacy fleet retirement.
• · Legacy fleets were fully retired as of April 2026, and the entire active controlled fleet had satellite WiFi by the reporting date.
• · Delta's revolving credit facility availability period was extended by two years to September 20, 2028.

04-08-2026

TELA Bio, Inc. announced the termination of CEO Antony Koblish without cause, effective August 3, 2026, and appointed Heather Getz as the new CEO and a Class II director. Ms. Getz brings extensive experience in healthcare and medical devices, including leading BioTelemetry from a $50M to $2.8B market cap. The company granted her significant inducement equity awards, including options for 1,365,000 shares and RSUs for 500,000 shares, with a base salary of $650,000 and target bonus of 100% of salary. The filing does not disclose any financial results or performance metrics, so no period-over-period comparisons are available.

• · Mr. Koblish's termination is treated as without cause; his existing equity awards remain outstanding pending a separation agreement.
• · Ms. Getz's appointment as CEO and director is effective August 3, 2026; her director term expires at the 2027 Annual Meeting.
• · Ms. Getz holds a CPA, an MBA from Villanova University, and a Director Certification from NACD.
• · The equity grants include a top-up provision: if the company completes equity financings within 18 months, additional grants will bring total shares subject to initial and top-up grants to 5% of outstanding shares post-financing.
• · Severance terms: 12 months base salary (18 months in a change of control) plus COBRA continuation for up to 12 months.

04-08-2026

McDonald's appointed Skye Anderson as President of McDonald's USA, effective August 4, 2026, succeeding Joe Erlinger, who is leaving after more than two decades with the company. Anderson, a 26-year McDonald's veteran and former COO of the U.S. business, will oversee nearly 14,000 U.S. restaurants and lead the company's largest market as it advances its 'McDonald's > NEXT' growth strategy. The leadership transition is part of a deliberate plan initiated earlier this year, with Erlinger remaining as an advisor until early 2027.

• · Anderson has more than 26 years of McDonald's experience.
• · Erlinger led the U.S. business for almost seven years.
• · Anderson previously served as COO of McDonald's USA, returning earlier this year as part of the transition plan.
• · Anderson's career includes finance leadership in Australia, field and zone leadership in the U.S., and creation of the company's Global Business Services.
• · Approximately 95% of McDonald's restaurants worldwide are owned and operated by independent local business owners.
• · McDonald's operates in over 100 countries.

04-08-2026

Evolus expanded its partnership with Symatese to commercialize the Estyme® injectable HA gel collection in Canada, Australia, and New Zealand, with commercialization expected in 2028. The agreement gives Evolus exclusive rights to market HA gels in every international market where it sells Jeuveau® and Nuceiva®, creating a consistent multi-product platform. The combined neurotoxin and dermal filler market in these three countries is approximately $500 million annually (60% neurotoxins, 40% fillers), and the deal is expected to be accretive to international gross margins.

• · Evolus will make an upfront payment to Symatese plus additional payments tied to regulatory approval milestones.
• · Evolus will purchase product from Symatese at an agreed transfer price and pay a mid-single digit royalty on net sales.
• · Symatese remains responsible for product development, manufacturing, clinical support, and regulatory activities.
• · Commercialization is expected in 2028, subject to regulatory approvals.
• · Estyme® is marketed in the U.S. under the brand name Evolysse®.
• · The agreement leverages Evolus' existing commercial organization, digital platform, and distribution infrastructure.

04-08-2026

Quanta Services, Inc. (NYSE: PWR) announced the pricing of a senior notes offering totaling $2.0 billion across three tranches: $500 million of 4.850% notes due 2029, $750 million of 5.300% notes due 2033, and $750 million of 5.550% notes due 2036. The offering is expected to close on August 6, 2026, with net proceeds used for general corporate purposes, including repayment of outstanding borrowings under its commercial paper program and senior credit facility. The notes are priced at slight discounts to par (99.950%, 99.757%, and 99.696% of face value, respectively).

• · The offering is made under an effective shelf registration statement on Form S-3 filed with the SEC on August 2, 2024.
• · Joint book-running managers vary by tranche: 2029 Notes (8 managers), 2033 Notes (8 managers), 2036 Notes (8 managers).
• · Proceeds will be used for general corporate purposes, including repayment of commercial paper program and senior credit facility borrowings.

04-08-2026

Lisata Therapeutics announced a 72% workforce reduction effective August 3, 2026, as part of cost-reduction initiatives to pursue strategic options. The company estimates $1.2 million in severance and termination costs through Q3 2026. In connection with the reduction, EVP of R&D and CMO Dr. Kristen K. Buck was terminated without cause and is entitled to 12 months of base salary, target bonus, and COBRA premiums; meanwhile, SVP James Nisco received a $200,000 retention bonus contingent on employment through year-end. Separately, on July 31, 2026, Lisata sued Kuva Labs Inc. and its subsidiary for breach of the March 2026 merger agreement, seeking damages for expected stockholder benefits.

• · The workforce reduction was approved by the board on August 3, 2026 and effective immediately.
• · Dr. Buck's termination is without Cause under her Amended and Restated Employment Agreement dated June 10, 2025.
• · James Nisco's retention bonus is payable within 30 days after December 31, 2026, subject to continued employment; if terminated without Cause, it is payable within 30 days of executing a release.
• · The lawsuit against Kuva Labs was filed in the Court of Chancery of the State of Delaware on July 31, 2026, alleging breach of the Merger Agreement dated March 6, 2026.

04-08-2026

Prologis, L.P. entered into a term loan credit agreement dated August 4, 2026, to finance its acquisition of SEGRO plc. The facility is led by JPMorgan Chase Bank, N.A. as administrative agent and sole lead arranger. The agreement includes financial covenants and pricing grids tied to credit ratings, with interest rates ranging from 0.675% to 1.55% per annum.

• · The credit agreement includes a 'Certain Funds Period' and provisions for extension of maturity date.
• · The facility is intended to finance the acquisition of at least a simple majority of SEGRO's outstanding shares.
• · The agreement includes guaranties from Prologis and certain affiliates.
• · The pricing grid includes an undrawn fee ranging from 0.10% to 0.30% per annum.

04-08-2026

FB Bancorp, Inc. announced the retirement of Dr. Stephen W. Hales from its Board of Directors, effective July 29, 2026, after 22 years of service. The departure was not due to any disagreement with the company. Concurrently, the Board appointed existing director Mark Romig as Chair of the Nominating/Governance Committee.

• · Dr. Hales' retirement was effective immediately on July 29, 2026.
• · Mark Romig was appointed Chair of the Nominating/Governance Committee effective immediately.
• · The retirement was in accordance with the Company's Director Guidelines.

04-08-2026

Galera Therapeutics, Inc. filed an 8-K on August 4, 2026, reporting a reverse stock split and a name change to 'Galera Therapeutics, Inc.' (previously 'Galera Therapeutics, Inc.'). The filing includes an amended and restated certificate of incorporation that reduces authorized common stock from 1,000 shares to 1,000 shares (no change) and eliminates the par value of $0.001 per share. The company also changed its name to 'Galera Therapeutics, Inc.' and reduced its authorized shares to 1,000 shares of common stock, $0.001 par value per share. No financial results or operational metrics were disclosed.

• · The company's name changed from 'Galera Therapeutics, Inc.' to 'Galera Therapeutics, Inc.' (no change).
• · Authorized common stock remains 1,000 shares with $0.001 par value per share.
• · The certificate of incorporation includes provisions for director liability elimination and indemnification.
• · No financial results, revenue, or operational metrics were provided in this filing.

04-08-2026

Jersey Mike's Subs Inc. filed an 8-K on August 4, 2026, disclosing an amended and restated certificate of incorporation. The company, incorporated in Delaware on February 24, 2026, has authorized 21 billion shares across three classes: 1 billion preferred, 10 billion Class A common, and 10 billion Class B common. The filing outlines voting rights, dividend restrictions, and transfer restrictions for Class B shares, reflecting a typical multi-class structure for a newly public company.

• · The company was incorporated under the name 'Jersey Mike's Inc.' on February 24, 2026, and has been renamed to 'Jersey Mike's Subs Inc.'
• · Class B Common Stock holders have no entitlement to dividends other than stock dividends, and no entitlement to assets upon liquidation.
• · Class B Common Stock is subject to transfer restrictions, requiring simultaneous transfer of an equal number of Common Units.
• · The Exchange Agreement and LLC Agreement are referenced, indicating a holding company structure with common units exchangeable for Class A shares.

04-08-2026

Lantheus Holdings, Inc. has entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC, under which Curium will acquire Lantheus for $102.50 per share in cash plus one contingent value right (CVR) per share. The transaction, unanimously approved by Lantheus's board, is structured as a merger of a Curium subsidiary into Lantheus, with the company surviving as a private entity. The deal is subject to stockholder approval, regulatory clearances, and other customary closing conditions, and includes a no-solicitation clause and termination fee provisions.

• · The merger consideration consists of $102.50 per share in cash plus one CVR per share representing the right to receive one or more Milestone Payments under a CVR Agreement.
• · The merger is expected to close no later than five business days after satisfaction or waiver of all conditions, with the closing to occur remotely.
• · The agreement includes a no-solicitation provision restricting Lantheus from soliciting alternative acquisition proposals.
• · Parent (Curium) has provided an Equity Commitment Letter, a Guarantee, and Debt Commitment Letters to support the financing of the transaction.
• · The merger is subject to approval by Lantheus stockholders, regulatory approvals, and other customary conditions set forth in Article VII.
• · Termination fees and other termination provisions are detailed in Article VIII of the agreement.

04-08-2026

GoDaddy entered into a Joinder and Thirteenth Amendment to its credit agreement, establishing $1.2 billion in new revolving credit commitments and terminating existing ones, with a final maturity of July 31, 2031. The amendment also includes $125 million in letter of credit commitments. This refinancing extends the maturity profile and provides additional liquidity, but does not change the company's overall debt level.

• · The amendment permanently terminates the existing revolving credit commitments.
• · The new revolving credit commitments have a final maturity date of July 31, 2031.
• · The amendment is effective as of July 31, 2026.
• · The amendment was arranged by a syndicate of major banks including RBC Capital Markets, BNP Paribas, HSBC, BofA Securities, Goldman Sachs, MUFG, Wells Fargo, and Morgan Stanley.

04-08-2026

Fusemachines Inc. (FUSEW) announced a $2.5 million strategic investment from existing investor Meteora Capital via a convertible note with a fixed conversion price of $4.20 per share, along with 2.05 million warrants exercisable at $4.20 per share. If all warrants are cash-exercised, the total potential capital infusion could reach $10.66 million. The financing is structured without toxic adjustment provisions, reflecting a long-term commitment, and proceeds will be used to accelerate the Agentic AI platform and enterprise deployments.

• · Convertible note and warrants have a fixed conversion/exercise price of $4.20 per share with no resets, ratchets, or floating-price mechanisms.
• · The investment is from an existing institutional investor, Meteora Capital.
• · Proceeds will fund development and commercialization of the Agentic AI platform, enterprise deployments, and product innovation.
• · Fusemachines was founded in 2013 and has offices in North America, Asia, and Latin America.

04-08-2026

Resideo Technologies completed the spin-off of its ADI Global Distribution business, establishing itself as a pure-play building technologies company. In connection with the spin-off, Resideo repaid $900 million of its Term Loan B credit facility and reduced its outstanding preferred stock by 150,000 shares to 350,000 shares. ADI began trading on the NYSE under the ticker 'ADIG', while Resideo continues to trade as 'REZI'.

• · Resideo shareholders received one share of ADI common stock for every two shares of Resideo common stock held as of July 20, 2026.
• · Resideo expects to make an additional ~$200 million repayment under its Term Loan B by the end of the third fiscal quarter.
• · The spin-off positions Resideo as a pure-play building technologies company with a 140-year heritage.
• · Resideo serves professional installers and integrators across HVAC controls, combustion, life safety, security, and water product segments.

04-08-2026

ADI Global Distribution Inc. (ADI) is being spun off from Resideo Technologies, Inc. via a pro rata distribution of 100% of ADI common stock to Resideo stockholders. Each Resideo stockholder will receive one share of ADI common stock for every two shares of Resideo common stock held as of July 20, 2026. ADI generated revenues of $4.8 billion in FY2025 and $1.2 billion in Q1 2026, and has applied to list on the NYSE under the symbol 'ADIG'.

• · The distribution is intended to be tax-free to Resideo common stockholders for U.S. federal income tax purposes, except for cash received in lieu of fractional shares.
• · Holders of Resideo preferred stock will exchange a portion of their shares for ADI preferred stock, with terms expected to be substantially similar.
• · A 'when-issued' trading market for ADI common stock may develop as early as three trading days prior to the distribution date.
• · Resideo will continue to trade on the NYSE under the symbol 'REZI' after the distribution.
• · The separation is expected to allow each company to pursue tailored capital structures and capital allocation strategies.

04-08-2026

Granite Construction entered into unwind agreements on August 4, 2026 to terminate capped call transactions related to its $273.7M 3.75% Convertible Senior Notes due 2028, which were previously called for redemption. The counterparties will pay cash to the company based on a five-day VWAP averaging period, with settlement expected around August 11, 2026. The company plans to use the proceeds, along with cash on hand, to settle conversions of the notes on August 12, 2026.

• · The cash settlement amount from the unwind agreements will be determined based on the volume-weighted average price per share of Granite's common stock during a five-day averaging period starting August 4, 2026.
• · Settlement of the unwind agreements and payment of cash settlement amounts are expected on or about August 11, 2026.
• · The company expects to settle conversions of the 2028 Notes on August 12, 2026 using proceeds from the unwind agreements and cash on hand.

04-08-2026

iBio, Inc. appointed Dr. Molly Carr as Chief Medical Officer, effective August 4, 2026. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, having held senior roles at Eli Lilly, GlaxoSmithKline, and other leading institutions. The company also granted her options to purchase 430,000 shares at $1.40 per share as an inducement award. This appointment strengthens iBio's clinical leadership as it advances its cardiometabolic pipeline, including IBIO-600 and IBIO-610, toward late-stage development.

• · Dr. Carr earned her M.D. from Columbia University College of Physicians and Surgeons and completed residency and fellowship in endocrinology at the University of Washington.
• · The option award was granted as an inducement material to employment under Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.
• · The option vests 25% on the one-year anniversary and 6.25% quarterly thereafter, with accelerated vesting upon change in control or certain involuntary terminations.
• · iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, cardiopulmonary diseases, and cancer.

04-08-2026

Better Home & Finance Holding Co appointed Daniel Lewis as Interim CEO, succeeding founder Vishal Garg who remains on the Board. The company issued preliminary Q2 2026 results showing funded loan volume of $1.67B (+38% YoY) and revenue of $54.7M (+28% YoY), but reported a net loss of $30.6M and negative adjusted EBITDA of -$14.0M. The company also raised its annualized cost reduction target to over $45M from $25M.

• · Daniel Lewis has over 30 years of operating, investment, and governance experience; previously CEO of Ascend Fundraising Solutions (2018-2023) and founder of Orange Capital LLC.
• · The company is pursuing the sale of its UK bank subsidiary, Birmingham Bank, through a process led by FT Partners.
• · Adjusted EBITDA for Q2 2026 includes a $6.5M benefit from a TRID reserve release related to loans originated prior to June 2022.
• · The company rescheduled its Q2 2026 earnings release and conference call to August 6, 2026 from August 10, 2026.
• · Lewis's compensation will be overwhelmingly tied to shareholder returns and long-term operating performance.

04-08-2026

Certara, Inc. announced the departure of Leif E. Pedersen from his role as President and Chief Commercial Officer, effective August 1, 2026. He will transition to a Senior Advisor role until December 31, 2026, after which his employment will be terminated without cause and he will receive severance benefits. This represents a significant change in the company's executive leadership.

• · The departure was announced on August 4, 2026, but was effective as of August 1, 2026.
• · Mr. Pedersen will serve as a Senior Advisor assisting with transition matters until December 31, 2026.
• · His employment agreement is dated July 30, 2020.
• · Severance benefits will be provided under the Company's Executive Officer Severance Policy.
• · The filing references a Definitive Proxy Statement filed on April 3, 2026, for details on post-employment payments.

04-08-2026

Barnwell Industries has entered into a definitive agreement to sell its remaining Hawaii development interests for a gross purchase price of $1.77 million, expecting net cash proceeds of approximately $1.5 million plus an additional pre-closing distribution of about $0.1 million. The transaction is part of a strategic transformation to simplify the portfolio, strengthen the balance sheet, and redeploy capital toward higher-return opportunities. While the sale generates immediate cash and reduces future commitments, the company notes there is no assurance that its broader strategic review will result in a transaction.

• · The transaction is expected to close before the end of fiscal year 2026 (September 30, 2026).
• · The sale includes indirect partnership interests in KKM Makai, LLLP and KD Kona 2013 LLLP, covering Increment 1 and Increment 2 of Lot 4-A at Ka‘upulehu on the Island of Hawaii.
• · The company expects to complete its exit from Hawaii by the end of fiscal 2026 with minimal additional cost.
• · Barnwell continues to evaluate potential business combinations with private operating companies that could benefit from its public-company platform, but there is no assurance any transaction will occur.

04-08-2026

Eton Pharmaceuticals appointed Danka Radosavljevic (age 42) as Chief Operating Officer, effective July 31, 2026. She previously served as Executive Vice President, Operations for over five years and has been with the company since 2017. Her compensation includes an annual base salary of $520,800 and a discretionary bonus target of 50% of base salary.

• · Ms. Radosavljevic has been with the company since 2017.
• · She previously oversaw quality, product development, regulatory, supply chain, and information systems.
• · The appointment was effective July 31, 2026, and the 8-K was filed on August 4, 2026.

04-08-2026

CAMP4 Therapeutics closed the second tranche of its private placement, raising approximately $50.1 million in gross proceeds, with total proceeds of $100 million across both closings. The funds will support the advancement of CMP-002, its lead candidate for SYNGAP1-related disorder, which recently received regulatory clearance to initiate a Phase 1/2 trial in Australia. While the financing strengthens the company's balance sheet, the company remains a clinical-stage biopharmaceutical with no approved products and faces inherent development risks.

• · CMP-002 is an antisense oligonucleotide (ASO) designed to upregulate SYNGAP1 gene expression, administered intrathecally.
• · Preclinical data for CMP-002 includes dose-dependent increases in SYNGAP protein in patient-derived neurons, reversal of behavioral phenotypes in a humanized mouse model, and statistically significant improvement in seizure phenotypes in a chemically induced seizure model.
• · SYNGAP1-related disorder is characterized by intellectual disability in 100% of patients, epilepsy in ~85%, severe behavioral problems in ~70%, sleep problems in ~60%, and ~30% non-verbal.
• · There are currently no approved disease-modifying therapies for SYNGAP1-related disorder.
• · The private placement securities were sold in a transaction not involving a public offering and have not been registered under the Securities Act.
• · Investors have been granted customary resale registration rights for shares underlying the pre-funded warrants.

04-08-2026

Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, including the election of four directors, ratification of BDO USA as auditor, an amendment to the 2020 Stock Incentive Plan increasing authorized shares from 4,500,000 to 6,500,000, an increase in authorized common stock, and the issuance of shares upon warrant exercise. Notably, Proposal 3 (Plan amendment) passed by a narrow margin (3,110,068 for vs. 2,840,658 against), while Proposal 4 (authorized share increase) and Proposal 6 (adjournment) received strong support. The company also disclosed that the Board retains discretion on whether to file the Charter Amendment despite stockholder approval.

• · Proposal 3 (Plan amendment) passed with 3,110,068 votes for, 2,840,658 against, and 105,575 abstentions, plus 10,823,826 broker non-votes.
• · Proposal 4 (authorized share increase) passed with 12,007,931 for, 4,643,286 against, and 228,910 abstentions.
• · Proposal 5 (warrant exercise share issuance) passed with 3,665,312 for, 2,267,592 against, and 123,397 abstentions.
• · Proposal 6 (adjournment) passed with 12,012,234 for, 4,297,352 against, and 570,541 abstentions, but was not needed as all other proposals passed.
• · The Board retains discretion on whether to file the Charter Amendment to increase authorized shares.

04-08-2026

Hillman Solutions Corp. reported Q2 2026 net sales of $442.3 million, a 9.8% increase YoY, and net income rose to $21.1 million from $15.8 million. However, adjusted diluted EPS remained flat at $0.17 per share. The company agreed to acquire Kanebridge Corp. for $315 million and raised its FY 2026 net sales and adjusted EBITDA guidance, while reiterating its free cash flow guidance midpoint.

• · The company repurchased approximately 1.7 million shares at an average price of $7.62 per share, totaling $13.3 million.
• · Subsequent to quarter end, Hillman refinanced its credit facilities with a new $735 million Term Loan B and a $375 million asset-based revolver.
• · H1 2026 net income was $16.4 million, essentially flat compared to $15.5 million in H1 2025, despite a 9.2% increase in net sales.
• · Free cash flow in H1 2026 surged to $70.2 million from $31.2 million in the prior year period, a 125% increase.
• · Gross debt increased slightly to $701.3 million from $693.1 million at year-end 2025, while net debt was essentially unchanged.
• · Leverage ratio (net debt to TTM Adjusted EBITDA) remained stable at 2.4x.
• · The updated FY 2026 net sales guidance range narrows to $1.670-1.720 billion, with the midpoint raised from $1.680 billion to $1.695 billion.
• · FY 2026 Adjusted EBITDA guidance was raised to approximately $285 million, up from the prior range of $275-285 million.
• · Free cash flow guidance was modestly adjusted to $105-115 million (midpoint $110 million), compared to the prior range of $100-120 million (midpoint $110 million).
• · Adjusted diluted EPS remained unchanged at $0.17 per share in Q2 2026 versus the prior year quarter.

04-08-2026

Griffon Corporation announced the closing of a joint venture for its AMES Australasia business, receiving $181 million in cash, a $49 million PIK note, and a 49% equity interest. The transaction is part of Griffon's portfolio optimization, with proceeds expected to be used for debt reduction and other corporate purposes. While the deal provides immediate liquidity and reduces exposure to the Australasian market, it also means Griffon will no longer consolidate the business and will share future profits with the new joint venture partners.

• · Goldman Sachs acted as financial advisor to Griffon and provided committed debt financing for the joint venture.
• · Houlihan Lokey Capital acted as financial advisor to Griffon's Board.
• · Clayton Utz acted as legal counsel to Griffon; Ashurst Australia acted as legal counsel to the investment group.
• · Griffon is the largest North American manufacturer of garage doors and rolling steel doors, and a leading provider of ceiling fans.

04-08-2026

Johnson & Johnson announced the retirement of Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, after a 21-year tenure during which the business grew to over $60 billion in annual revenue. She will be succeeded by Tom Cavanaugh, currently Company Group Chairman for North America, effective September 1, 2026. The transition is described as smooth and planned, with no negative financial impact indicated.

• · Jennifer Taubert's retirement follows a 21-year tenure at Johnson & Johnson.
• · Tom Cavanaugh joined Johnson & Johnson in 2017 and previously spent nearly 15 years at Celgene.
• · Tom Cavanaugh will join the Johnson & Johnson Executive Committee effective September 1, 2026.
• · Jennifer Taubert was recognized for 10 consecutive years among Fortune’s Most Powerful Women.

04-08-2026

Kustom Entertainment (Nasdaq: KUST) closed a $6.1 million divestiture of its legacy video solutions business to Cycurion (Nasdaq: CYCU), completing its strategic pivot to a pure-play live entertainment and ticketing technology company. The transaction includes $1.25 million upfront cash, a $4.25 million secured promissory note at 7% interest, and $600,000 in 12% yielding preferred equity. The company is now focused on expanding its Country Stampede festival and proprietary ticketing platform, but the divestiture represents a reduction in business scope and the loss of a legacy revenue stream.

• · The transaction closed on August 3, 2026, under amended terms (Amendment No. 1 and Forbearance/Extension Agreement)
• · The $1.25M upfront cash includes a $250,000 non-refundable cash payment delivered at amendment signing
• · The $4.25M secured promissory note has a 36-month term with 7.0% annual interest
• · The $600,000 Series H Preferred Stock has a $1.45 conversion price with anti-dilution protections, senior liquidation preferences, class voting rights, and registration rights
• · Country Stampede celebrated its 30th Anniversary in June 2026 and is expanding to Gilley's Park City in Park City, KS (Wichita metro area) for 2027, doubling capacity to 35,000 fans per show
• · The company plans more than 20 live event days across 2026 and 2027

04-08-2026

Steel Dynamics announced a CEO succession plan: Theresa E. Wagler will become President and CEO effective January 1, 2027, succeeding Mark D. Millett who will transition to Executive Chairman. Richard A. Poinsatte will succeed Wagler as CFO on the same date. The board also approved several senior leadership changes effective September 1, 2026, to support long-term growth and talent development.

• · Theresa Wagler has been with Steel Dynamics for 28 years and served as EVP and CFO since 2007.
• · Richard Poinsatte joined Steel Dynamics in 2000 and has served as Treasurer since 2008.
• · Barry Schneider is taking a new strategic growth role as EVP and Chief Technology Officer, adding oversight of decarbonization strategy.
• · Miguel Alvarez will assume executive oversight of metals recycling in addition to aluminum investments; he previously led the metals recycling platform from March 2022 to October 2025.
• · James Anderson will assume executive oversight of steel fabrication in addition to long products steel; he previously led the steel fabrication business from 2015 to 2024.
• · Christopher Graham was promoted to EVP and COO of Flat Rolled Steel Operations in recognition of the scale and growth opportunities of that business.
• · The succession plan was unanimously approved by the board of directors.
• · Wagler will become a member of the board effective immediately.
• · Millett co-founded the company over 30 years ago.

04-08-2026

Columbus Acquisition Corp. issued a $25,000 convertible promissory note to WISeSat.Space Corp. on July 30, 2026, to fund 50% of an extension payment under the Business Combination Agreement dated November 9, 2025. The note is non-interest bearing and convertible into securities at $10.00 per unit, or into shares at $5.00 per share upon certain termination events. This financing supports the ongoing merger process, but the small principal amount indicates limited near-term financial impact.

• · The note is non-interest bearing (Section 3).
• · Repayment is triggered by BCA termination (except by Maker under Section 10.1(e)), consummation of the Business Combination, or winding up of Maker.
• · Upon BCA termination by Maker under Section 10.1(e), Maker may elect to repay in cash or convert into shares at $5.00 per share.
• · Payee waives any claims against the Trust Account established for public shareholders (Section 10).
• · The note is automatically assigned to the Seller (WISeKey) immediately prior to consummation of the BCA transactions.

04-08-2026

American Rebel Holdings, Inc. entered into an Exchange Agreement with Horberg Enterprises, LP on July 28, 2026, exchanging 6,800 shares of Series D Convertible Preferred Stock (aggregate Stated Value of $51,000) for 51 shares of newly created Series E Preferred Stock at an effective price of $1,000 per share. The exchange is intended to qualify under Section 3(a)(9) of the Securities Act, with no additional consideration paid by the investor, and the holding period of the Series E shares will tack back to the original Series D issuance date of October 1, 2025. The Series D shares will be cancelled upon issuance of the Series E shares, and the company represents it has not received any consideration other than the surrender of the Preferred Shares.

• · The exchange is intended to comply with Section 3(a)(9) of the Securities Act of 1933, meaning it is exempt from registration.
• · The Series E Preferred shares will be issued in book-entry form and held by the company's securities counsel.
• · The company represents that no governmental consent, approval, or filing is required for the exchange.
• · The investor represents that it is an 'accredited investor' as defined in Regulation D.
• · The exchange agreement includes a waiver of jury trial by the company and a prevailing party attorneys' fees clause.

04-08-2026

StratCap Digital Infrastructure REIT announced leadership changes effective July 31, 2026. James A. Condon resigned as Chairman, Director, and President of the company, as well as President of the Advisor and Sponsor, with no disagreement cited. Adam Baxter was appointed Chairman and President, while Erik Rostvold was appointed Head of Data Center Investments, succeeding Bryan B. Marsh III, who resigned. These changes are routine governance transitions with no disclosed financial impact.

• · Adam Baxter, age 50, has served on the Board since September 2024 and as Secretary since July 2025.
• · Baxter was a Managing Director at Macquarie Group from May 2005 to February 2023.
• · Erik Rostvold, age 49, has been Chief Risk Officer of the Advisor and Sponsor since October 2024.
• · Rostvold has been involved in the formation and capital raise for over $20B in alternative investment offerings.
• · No family relationships or related-party transactions were disclosed for Baxter or Rostvold.

04-08-2026

Oglethorpe Power Corporation announced that Heather H. Teilhet, current Executive Vice President of External Affairs, has been selected by the Georgia Electric Membership Corporation's board as the next President/CEO, effective January 4, 2027. Ms. Teilhet will resign from her current role on January 1, 2027, and will assist with the transition of her responsibilities. The company will begin a search for her replacement.

• · The appointment is effective January 4, 2027.
• · Ms. Teilhet will resign from her current position on January 1, 2027.
• · She will remain with the company through her resignation date to assist with the transition.
• · The company will begin a search for Ms. Teilhet's replacement as Executive Vice President, External Affairs.

04-08-2026

Marqeta reported Q2 2026 financial results with Total Processing Volume (TPV) growing 32% YoY to $120 billion, Net Revenue up 17% to $176 million, and Gross Profit up 17% to $122 million. The company achieved GAAP Net Income of $8 million (vs. a net loss of $1 million in Q2 2025) and Adjusted EBITDA of $37 million (+31% YoY). However, the company's Q3 2026 guidance calls for a sharp deceleration, with Net Revenue growth of only 6-8% and Gross Profit growth of 5-7%, well below the prior quarter's 17% growth rates. The Board also authorized a $150 million share repurchase program.

• · Gross Margin remained flat at 69% in Q2 2026 vs Q2 2025.
• · Total Operating Expenses increased 4% YoY to $118.2 million in Q2 2026.
• · The company's Q3 2026 guidance implies a significant deceleration: Net Revenue growth of 6-8% and Gross Profit growth of 5-7%, compared to 17% growth in Q2 2026.
• · FY 2026 guidance: Net Revenue growth 12-13%, Gross Profit growth 11-12%, Adjusted EBITDA growth in the low 30s.
• · The company completed a one-for-four reverse stock split effective June 30, 2026, which reduced weighted-average shares outstanding by a factor of four and increased per-share amounts by a factor of four for all periods presented.
• · Weighted-average basic shares outstanding decreased from 115.4 million in Q2 2025 to 105.5 million in Q2 2026, partly due to the reverse stock split.

04-08-2026

On July 31, 2026, Celanese Corporation amended its revolving credit agreement, increasing debt capacity through higher thresholds for certain debt baskets (from $900M to $1.05B) and updating the pricing grid tied to credit ratings. The amendment also establishes a multi-year step-down covenant relief period, allowing the consolidated leverage ratio to start at 6.00x and gradually decline to 4.00x by mid-2030, while retaining the option to return to a 3.50x covenant earlier if leverage improves. This provides Celanese with greater financial flexibility during a period of elevated leverage, though the extended 6.00x starting covenant and high thresholds indicate elevated debt levels and potential credit risk.

• · Effective date of the amendment is July 31, 2026.
• · The pricing grid links SOFR loan margins and commitment fees to Celanese’s credit ratings from S&P, Moody’s, and Fitch, with margins ranging from 1.00% (Level 1) to 2.25% (Level 7).
• · Covenant Relief Period can be terminated early at the Company's election if the Consolidated Leverage Ratio is not greater than 3.50:1.00 upon a test date.
• · Financial covenant (Consolidated Leverage Ratio) starts at 6.00x for Q2 2026 and steps down over eight years to 4.00x by Q2 2030 and thereafter; the pre-amendment covenant was 3.50x.
• · Permitted Receivables Financing cap remains unchanged at $750M.
• · The amendment corrects a cross-reference in Section 10.01 from Section 3.03(c) to Section 3.03(b).
• · Provides for a 0.25x reduction in the leverage covenant for each Qualifying Disposition during the Covenant Relief Period (first disposition excluded).
• · A Qualifying Acquisition can trigger a temporary increase in the leverage covenant to 4.25x for four quarters, limited to two such periods total.
• · The consenting lenders include not less than the Required Lenders, and BofA Securities acted as lead arranger.

04-08-2026

BranchOut Food Inc. settled a lawsuit with former employee Doug Durst and Chase Innovations, agreeing to pay a total of $303,390 in cash and issue a warrant for 57,600 shares. The settlement resolves claims of breach of contract and failure to pay wages, with the company denying any wrongdoing. The cash payments include an initial $147,500 (split between wage and non-wage components) plus five monthly installments of $20,000, and a separate $55,890 payment to Chase Innovations.

• · The lawsuit was filed in Washington State King County Superior Court, Civil Action No. 25-2-18652-1-SEA.
• · Branchout filed counterclaims against Durst alleging Breach of Contract and various tort claims.
• · If Branchout is more than 10 business days late on any payment to Durst, the remaining balance becomes immediately due after a 5-business-day cure period.
• · The warrant strike price is the lower of $4.125 or the market price at the closing bell on the first trading day after full execution.
• · The agreement includes mutual releases and a confidentiality clause regarding the consideration amounts.
• · Durst is represented by counsel and acknowledges having time to review the agreement.

04-08-2026

On July 29, 2026, director Shawn Matthews resigned from the Board of Streamex Corp., effective immediately, with no disagreement with the company. The company has identified a potential candidate to fill the vacancy before year-end, but no appointment is guaranteed and the seat may remain unfilled.

• · Resignation was not due to any disagreement with the company on operations, policies, or practices.
• · The company has identified a potential qualified candidate but no assurance of nomination or appointment.
• · The company reserves the right to leave the vacancy unfilled.

04-08-2026

Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with its landlord, BMR-Sidney Research Campus LLC, to partially terminate its lease at 200 Sidney Street, Cambridge, MA. The agreement immediately surrenders approximately 21,295 rentable square feet (first and fourth floors) and terminates the remaining 47,341 rentable square feet effective December 31, 2026. Total monetary consideration includes a $2.24M letter of credit increase, a $3.85M termination fee payable in January 2027, and $500,000 in common stock to the landlord. The company also reduces its allocated parking spaces from 68 to zero.

• · The partial termination of the first and fourth floors is effective immediately upon execution (July 31, 2026) and relieves Seres of surrender/decontamination obligations due to the AbbVie sublease.
• · The remaining premises consist of 47,341 rentable square feet across basement (14,958 sq ft), first floor (31,375 sq ft), and second floor (1,008 sq ft).
• · Tenant's pro rata share of the building is reduced to 25.10%.
• · The lease termination is contingent on Seres completing Turnover Requirements (including an Exit Survey) and satisfying the Letter of Credit increase and equity issuance obligations.
• · Landlord will apply the Letter of Credit toward all Base Rent, Additional Rent, and Operating Expenses through the Expiration Date, with no post-termination reconciliation.
• · The equity issuance of $500,000 in common stock will be made under Seres' effective S-3 registration statement and will be freely tradeable.

04-08-2026

Cartesian Growth Corporation II (REEUF) filed an 8-K on August 4, 2026, disclosing an amendment to its Amended and Restated Memorandum and Articles of Association. The amendment extends the deadline to consummate a business combination from the original date to August 5, 2027, and updates the redemption and liquidation procedures if no deal is completed by that date. The filing also includes items related to a change in the fiscal year (5.03) and shareholder votes (5.07), indicating shareholder approval was obtained for the extension.

• · The amendment was approved by shareholders (Item 5.07).
• · The company also changed its fiscal year (Item 5.03).
• · The Termination Date for the business combination is August 5, 2027.
• · If no business combination is consummated by the Termination Date, the company must cease operations, redeem public shares within ten business days, and then liquidate and dissolve.
• · Public shareholders have redemption rights if the articles are amended to modify the substance or timing of the redemption obligation or other pre-business combination rights.

04-08-2026

SSR Mining Inc. entered into a Second Amended and Restated Credit Agreement dated July 31, 2026, amending and restating its existing $400 million revolving credit facility. The new agreement maintains the same $400 million commitment and includes updated pricing grids based on net leverage ratio, with an initial Applicable Margin at Level 1 (lowest). The facility is provided by a syndicate led by The Bank of Nova Scotia as Administrative Agent, with Canadian Imperial Bank of Commerce, Royal Bank of Canada, and Bank of Montreal as co-arrangers.

• · The credit agreement is a second amendment and restatement of the existing credit agreement dated August 15, 2023.
• · The facility is a revolving credit facility with a total commitment of $400 million.
• · Initial Applicable Margin is set at Level 1 (≤1.0x Net Leverage Ratio): 175 bps for CORRA/SOFR loans, 75 bps for Canadian Prime/Base Rate loans, 116.67 bps for non-financial letters of credit, and 35 bps standby fee.
• · The agreement includes provisions for letters of credit, swingline loans, and various financial covenants and events of default.
• · The agreement is governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein.

04-08-2026

Waste Connections, Inc. completed an underwritten public offering of C$700 million aggregate principal amount of senior notes, comprising C$300 million of 4.200% Senior Notes due 2033 and C$400 million of 4.550% Senior Notes due 2036. The notes are senior unsecured obligations ranking equally with existing unsubordinated debt and are not guaranteed by subsidiaries. The offering was made under an existing shelf registration statement and a Canadian private placement.

• · The notes were issued under the Indenture dated November 16, 2018, as supplemented by the Twelfth Supplemental Indenture dated August 4, 2026.
• · Interest on the notes will be paid semi-annually on March 4 and September 4, beginning March 4, 2027.
• · The 2033 Notes mature on September 4, 2033; the 2036 Notes mature on September 4, 2036.
• · First coupon payments are C$2.45671233 per C$100 for the 2033 Notes and C$2.661438356 per C$100 for the 2036 Notes.
• · Make-whole redemption provisions apply before the par call dates (July 4, 2033 for 2033 Notes; June 4, 2036 for 2036 Notes); thereafter redeemable at par.
• · Change of control put option at 101% of principal plus accrued interest.
• · Covenants include limitations on liens, sale-leaseback transactions, and mergers/sales of substantially all assets.
• · Events of default include payment defaults (30-day cure), covenant breaches (60-day cure), and bankruptcy/insolvency events.
• · Holders of 25% in principal amount can accelerate the notes upon an event of default.

04-08-2026

Lumen Technologies reported Q2 2026 revenue of $2.805 billion, down 9% YoY, with a net loss of $(201) million, improved from a $(915) million loss a year ago. Strategic revenue grew to 53% of business revenue, and the company closed the Alkira acquisition to enhance its digital networking capabilities. However, total revenue declined, Mass Markets revenue fell 40% YoY, and adjusted EBITDA excluding special items decreased to $802 million from $877 million.

• · Strategic revenue increased to 53% of total business revenue, up from 51% in Q1 2026.
• · Q2 2026 diluted loss per share was $(0.20), compared to $(0.92) in Q2 2025; excluding special items, diluted loss per share was $(0.07) vs $(0.03) in Q2 2025.
• · Net cash provided by operating activities was $971 million in Q2 2026, up from $570 million in Q2 2025.
• · Capital expenditures were $902 million in Q2 2026, up from $891 million in Q2 2025.
• · Full-year 2026 outlook: Adjusted EBITDA excluding special items $3.1-$3.3 billion; Free cash flow excluding special items $1.9-$2.1 billion; Capital expenditures excluding special items $3.2-$3.4 billion.
• · Q2 2026 revenue by segment: Large Enterprise $794M (up 4% YoY), Mid-Market Enterprise $435M (down 8% YoY), Public Sector $490M (up 1% YoY), Wholesale $653M (down 5% YoY), International and Other $72M (down 10% YoY).
• · Q2 2026 revenue by product: Strategic $1,289M (up 14% YoY), Legacy $1,155M (down 15% YoY).
• · Q2 2026 net loss margin was (7.2)% vs (29.6)% in Q2 2025; excluding special items, net loss margin was (2.6)% vs (0.9)%.
• · Adjusted EBITDA margin was 21.3% in Q2 2026 vs 23.4% in Q2 2025; excluding special items, 28.6% vs 28.4%.
• · Q2 2026 stock-based compensation expense was $18 million, up from $12 million in Q2 2025.

04-08-2026

3D Systems announced that Dr. Jeffrey Graves will step down as President, CEO, and Board member, continuing in his role until a successor is appointed later this year, after which he will serve as a consultant for six months. The Board has initiated a CEO search with an executive search firm. The announcement accompanies the company's Q2 2026 financial results release, with no specific financial metrics or performance comparisons provided in this filing.

• · CEO transition plan announced alongside Q2 2026 financial results.
• · Dr. Graves joined 3D Systems in May 2020.
• · Company focuses on Aerospace & Defense, Data Center Infrastructure, Med Tech, and Dental markets.
• · Board has engaged an executive search firm for the CEO search.

04-08-2026

Ingles Markets announced the resignation of board member Brenda S. Tudor, effective September 8, 2026, citing family health reasons. The board plans to appoint an additional independent member to the Audit Committee and elect a new board member to fill the vacancy. No financial impact or disagreement was disclosed.

• · Resignation effective September 8, 2026
• · Board plans to appoint an additional independent board member to join the Audit Committee
• · Board plans to elect a new board member to fill the vacancy
• · Resignation is not due to any disagreement with the company

04-08-2026

Burlington Stores announced the departure of EVP and CHRO Matthew Pasch, effective September 1, 2026, with severance benefits including pro-rata vesting of his 2024 performance-based RSU. John Pershing, a seasoned HR leader with experience at Barnes & Noble, Canadian Tire, Ascena, and Best Buy, is expected to succeed him in October 2026. The transition appears orderly with a planned handoff, though the filing contains no financial impact or performance metrics.

• · Mr. Pasch's departure is effective September 1, 2026.
• · John Pershing is expected to assume the CHRO role in October 2026.
• · Pershing's most recent role was CHRO at Barnes & Noble (2024-2025).
• · Pershing previously spent over 20 years at Best Buy in various leadership roles.